Low molecular weight heparins versus unfractionated heparin for thromboprophylaxis in surgery, cancer and general medicine: a review of the cost-effectiveness and safety
CADTH
Record ID 32014000130
English
Authors' recommendations:
The evidence from Canadian settings supports the cost-effectiveness of LMWH compared to UFH in medical patients. In terms of HIT or bleeding risk, LMWH was superior to UFH in patients following surgery, but similar or superior to UFH in general medical patients. The results of the findings should be interpreted with caution due to the limitations of methodological quality and various heterogeneities in dosing regimens, time horizon, study perspective and assumptions.
Details
Project Status:
Completed
Year Published:
2013
URL for published report:
http://www.cadth.ca/media/pdf/htis/jul-2013/RC0460%20LMWH%20vs%20UFH%20final.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Humans
- Venous Thrombosis
- Heparin, Low-Molecular-Weight
- Heparin
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.